Home Biosimilar Antibodies Metabolism Factor Xa Abelacimab (Anti-F11 / Factor XI)
For research use only. Not for use in humans.

Abelacimab (Anti-F11 / Factor XI)

Synonyms: PTA， coagulation factor XI

Abelacimab (Anti-F11 / Factor XI) is a human anti-factor XI (FXI) monoclonal antibody with potential anti-thrombotic activity. MW: 144.36 KD.

Abelacimab (Anti-F11 / Factor XI)

Quality Control

Batch: A290501 Purity: 99% Protein concentration: 5.53mg/ml Endotoxin Level: ＜1EU/mg
99

Specificity

Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Abelacimab (Anti-F11 / Factor XI) is a human anti-factor XI (FXI) monoclonal antibody with potential anti-thrombotic activity. MW: 144.36 KD.
References

Product Details

CAS No. 2098724-83-3
Molecular Weight 144.36
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT07493304 RECRUITING Drug: REGN7508|Drug: Apixaban Venous Thromboembolism (VTE) Regeneron Pharmaceuticals 2026-08-31 PHASE3
NCT07739888 NOT_YET_RECRUITING Atrial Fibrillation (AF) Novartis Pharmaceuticals 2027-12-30 PHASE3
NCT07626411 RECRUITING Drug: REGN7508|Drug: Apixaban|Drug: Placebo Atrial Fibrillation (AF) Regeneron Pharmaceuticals 2026-08-10 PHASE3
NCT07318610 RECRUITING Drug: REGN7508|Drug: REGN9933|Drug: Placebo|Drug: Rivaroxaba Peripheral Artery Disease (PAD) Regeneron Pharmaceuticals 2026-07-10 PHASE3
NCT07697599 NOT_YET_RECRUITING Drug: REGN7508|Drug: REGN9933|Drug: Placebo Venous Thromboembolism (VTE) Regeneron Pharmaceuticals 2026-08-20 PHASE3
NCT07430956 RECRUITING Drug: REGN7508|Drug: REGN9933|Drug: Placebo Atrial Fibrillation (AF) Regeneron Pharmaceuticals 2026-04-03 PHASE3

(data from https://clinicaltrials.gov, updated on 2026-08-19)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.